First AD

Second AD

cCRT-to-Durvalumab Interval in Limited Stage LS-SCLC

In patients with LS-SCLC, what would you consider to be a reasonable time interval between 

 of consolidation therapy with a PD-L1 inhibitor?

What is the role of SBRT in earlier stages of disease vs cCRT followed by durvalumab?

Clinical

® Clinical Focus page includes a listing of all specialities covered across  OncLive.com, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, hematologic malignancies, and gynecologic cancers. Each individual specialty page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research.


Lung Cancer

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

OncLive Peer Exchange® 

® Peer Exchange video program comprises lively expert panel discussions feature peer-to-peer exchanges providing authoritative insights, opinions, and perspectives on important issues facing today’s health care professionals. Episodes focus on updates and insights across solid and hematologic malignancies, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecological cancers, and hematologic malignancies. 

Video Series

ASCO 2024: Immunotherapy for the Treatment of Small Cell Lung Cancer

Peer Exchange

Tarita O. Thomas, MD, PhD discusses patients with LS-SCLC, and what she would consider to be a reasonable time interval between completion of cCRT to initiation of consolidation therapy with a PD-L1 inhibitor. The panel also discusses the potential for curative-intent immunotherapy with durvalumab for earlier stages of SCLC.